title: Negative symptoms and neuroleptics in catatonic schizophrenia.
abstract: The association between neuroleptic treatment and the negative symptom dimension (ND) was evaluated in 1528 schizophrenia patients. In patients receiving more than 820 mg chlorpromazine (CPZ), those with catatonic-type disorder had significantly (p<0.05) higher ND scores than those in any of the other diagnostic subtypes. Even in patients receiving 450 mg CPZ or more, catatonic patients had significantly (p=0.046) higher ND scores than other patients. Patients with catatonic schizophrenia are highly vulnerable to negative symptoms related to neuroleptic drugs, probably because of a defect in their dopaminergic neuronal pathways.
authors.affiliation: Department of Psychiatry, University of Turku, FIN-20520 Turku, Finland. Raimo.K.R.Salokangas@tyks.fi
authors.forename: Raimo K R
authors.initials: RK
authors.lastname: Salokangas
authors.forename: Teija
authors.initials: T
authors.lastname: Honkonen
authors.forename: Eija
authors.initials: E
authors.lastname: Stengård
authors.forename: Anna Maija
authors.initials: AM
authors.lastname: Koivisto
authors.forename: Jarmo
authors.initials: J
authors.lastname: Hietala
mesh_terms: D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D014150:Antipsychotic Agents / Q000009:adverse effects*; D002746:Chlorpromazine / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012559:Schizophrenia / Q000188:drug therapy; D012560:Schizophrenia, Catatonic / Q000188:drug therapy* / Q000523:psychology*; D012565:Schizophrenic Psychology
chemical_list: D014150:Antipsychotic Agents; D002746:Chlorpromazine